Evaluation of oral selenium on blood levels of Anti-TG in patients with autoimmune thyroiditis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180211038689N1

Enrollment

Registered

2019-11-09

Start date

2018-01-24

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune hypothyroidism. Other specified hypothyroidism

Interventions

Intervention 1: placebo(Wheat bran),similar capsules with selenium capsules and no effective ingredients, the manufacturing company is Mashhad Pharmaceutical Faculty and Take 1.7 Levothyroxin per day

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: the patients with autoimmune thyroiditis within the age limit of 18-65.

Exclusion criteria

Exclusion criteria: Patients with acute systemic disease kidney failure liver failure Heart disease Malabsorption illness Use of Selenium Supplements overthe past 6 months

Design outcomes

Primary

Measure	Time frame
Anti-TG antibody. Timepoint: Before intervention, three months after intervention. Method of measurement: IRMA.	—

Secondary

Measure	Time frame
TSH. Timepoint: Before and three month after intervention. Method of measurement: Elisa kit lab.;Free T4. Timepoint: Before and three month after intervention. Method of measurement: Elisa kit lab.;T3. Timepoint: Before intervention and three month after intervention. Method of measurement: Elisa kit lab.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Akbari Rad

Mashhad University of Medical Sciences

akbariradm@mums.ac.ir+98 51 3840 6757

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026